Publication:
Bone Mineral Density in Patients Receiving Isotretinoin and Acitretin

dc.authorscopusid6602342527
dc.authorscopusid59435356300
dc.authorscopusid7004347982
dc.authorscopusid6602757748
dc.authorscopusid6506103281
dc.authorscopusid11140283600
dc.authorscopusid11140283600
dc.contributor.authorCantürk, F.
dc.contributor.authorSaraç, N.
dc.contributor.authorAydin, F.
dc.contributor.authorCanbaz, F.C.
dc.contributor.authorAlayli, G.
dc.contributor.authorAkyol, Y.
dc.contributor.authorCantürk, T.
dc.date.accessioned2025-12-11T02:23:05Z
dc.date.issued2004
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Cantürk] Ferhan, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Saraç] Nalan, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Aydin] Fatma, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Canbaz] Fevziye, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Alayli] Gamze, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Akyol] Yeşim, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Cantürk] Tayyar, Faculty of Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractBackground and design: Isotretinoin and acitretin, known as retinoids, are synthetic derivaties of vitamin A. They have been known to cause a variety of skeletal side effects. The aim of the study was to determine whether the patients receiving synthetic retinoids are under the risk of osteoporosis. Material and Method: Nineteen patients who received 0.5 mg/kg/day dose of acitretin (n=16) and isotretinoin (n=3) were included in this study. Bone mineral density (g/cm2) of left hip (neck, trochanter) and lumbar spine (L2-L4) were measured by Dual Energy X-Ray Absorptiometry before and at the sixth month of the therapy. Results: We didn't find statistically significant difference in bone mineral density (p>0.05). Conclusion: Short term (six months) isotretinoin and acitretin with a low dose of 0.5 mg/kg/day were not due to osteoporosis at the lumbar spine and the hip.en_US
dc.identifier.endpage194en_US
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-13244297083
dc.identifier.scopusqualityN/A
dc.identifier.startpage191en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/47877
dc.identifier.volume38en_US
dc.identifier.wosqualityN/A
dc.language.isotren_US
dc.relation.ispartofTurkderm Deri Hastaliklari ve Frengi Arsivien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcitretinen_US
dc.subjectIsotretinoinen_US
dc.subjectOsteoporosisen_US
dc.subjectRetinoiden_US
dc.titleBone Mineral Density in Patients Receiving Isotretinoin and Acitretinen_US
dc.title.alternativeİzotretinoin Ve Asitretin Kullanan Hastalarda Kemik Mineral Yoğunluklarıen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files